Protein Drug Targets
Overview <table class="infobox infobox-protein"> <tr> <th class="infobox-header" colspan="2">Protein Drug Targets</th> </tr> <tr> <td class="label">Target</td> <td>Protein</td> </tr> <tr> <td class="label">BACE1</td> <td>[Beta-secretase](/entities/bace1)</td> </tr> <tr> <td class="label">[Gamma-secretase](/entities/gamma-secretase)</td> <td>[PSEN1](/entities/psen1)/2 complex</td> </tr> <tr> <td class="label">[Amyloid-beta](/proteins/amyloid-beta)</td> <td>Aβ aggregation</td> </tr> <tr> <td class="label">Amyloid-beta</td> <td>Aβ production</td> </tr> <tr> <td class="label">Target</td> <td>Protein</td> </tr> <tr> <td class="label">Tau kinases</td> <td>GSK3β, [CDK5](/proteins/cdk5)</td> </tr> <tr> <td class="label">Tau aggregation</td> <td>[MAPT](/proteins/tau)</td> </tr> <tr> <td class="label">Tau</td> <td>Tau clearance</td> </tr> <tr> <td class="label">Tau</td> <td>Tau clearance</td> </tr> <tr> <td class="label">Target</td> <td>Protein</td> </tr> <tr> <td class="label">AChE</td> <td>Acetylcholinesterase</td> </tr> <tr> <td class="label">[NMDA receptor](/entities/nmda-receptor)</td> <td>GRIN1/2</td> </tr> <tr> <td class="label">Muscarinic receptor</td> <td>CHRM1, CHRM3</td> </tr> <tr> <td class="label">5-HT receptor</td> <td>HTR2A, HTR6</td> </tr> <tr> <td class="label">Target</td> <td>Protein</td> </tr> <tr> <td class="label">[TREM2](/proteins/tr
...
Protein Drug Targets
Overview <table class="infobox infobox-protein"> <tr> <th class="infobox-header" colspan="2">Protein Drug Targets</th> </tr> <tr> <td class="label">Target</td> <td>Protein</td> </tr> <tr> <td class="label">BACE1</td> <td>[Beta-secretase](/entities/bace1)</td> </tr> <tr> <td class="label">[Gamma-secretase](/entities/gamma-secretase)</td> <td>[PSEN1](/entities/psen1)/2 complex</td> </tr> <tr> <td class="label">[Amyloid-beta](/proteins/amyloid-beta)</td> <td>Aβ aggregation</td> </tr> <tr> <td class="label">Amyloid-beta</td> <td>Aβ production</td> </tr> <tr> <td class="label">Target</td> <td>Protein</td> </tr> <tr> <td class="label">Tau kinases</td> <td>GSK3β, [CDK5](/proteins/cdk5)</td> </tr> <tr> <td class="label">Tau aggregation</td> <td>[MAPT](/proteins/tau)</td> </tr> <tr> <td class="label">Tau</td> <td>Tau clearance</td> </tr> <tr> <td class="label">Tau</td> <td>Tau clearance</td> </tr> <tr> <td class="label">Target</td> <td>Protein</td> </tr> <tr> <td class="label">AChE</td> <td>Acetylcholinesterase</td> </tr> <tr> <td class="label">[NMDA receptor](/entities/nmda-receptor)</td> <td>GRIN1/2</td> </tr> <tr> <td class="label">Muscarinic receptor</td> <td>CHRM1, CHRM3</td> </tr> <tr> <td class="label">5-HT receptor</td> <td>HTR2A, HTR6</td> </tr> <tr> <td class="label">Target</td> <td>Protein</td> </tr> <tr> <td class="label">[TREM2](/proteins/trem2)</td> <td>TREM2</td> </tr> <tr> <td class="label">CD33</td> <td>CD33</td> </tr> <tr> <td class="label">NLRP3</td> <td>[NLRP3 inflammasome](/entities/nlrp3-inflammasome)</td> </tr> <tr> <td class="label">Target</td> <td>Protein</td> </tr> <tr> <td class="label">[Alpha-synuclein](/proteins/alpha-synuclein)</td> <td>SNCA</td> </tr> <tr> <td class="label">Alpha-synuclein</td> <td>SNCA</td> </tr> <tr> <td class="label">Alpha-synuclein</td> <td>SNCA</td> </tr> <tr> <td class="label">GBA</td> <td>Glucocerebrosidase</td> </tr> <tr> <td class="label">Target</td> <td>Protein</td> </tr> <tr> <td class="label">D2 receptor</td> <td>DRD2</td> </tr> <tr> <td class="label">MAO-B</td> <td>MAO-B</td> </tr> <tr> <td class="label">COMT</td> <td>COMT</td> </tr> <tr> <td class="label">A2A receptor</td> <td>ADORA2A</td> </tr> <tr> <td class="label">Target</td> <td>Protein</td> </tr> <tr> <td class="label">LRRK2 kinase</td> <td>LRRK2</td> </tr> <tr> <td class="label">Target</td> <td>Protein</td> </tr> <tr> <td class="label">SOD1</td> <td>Superoxide dismutase 1</td> </tr> <tr> <td class="label">SOD1</td> <td>SOD1</td> </tr> <tr> <td class="label">[C9orf72](/entities/c9orf72)</td> <td>C9orf72</td> </tr> <tr> <td class="label">FUS</td> <td>FUS</td> </tr> <tr> <td class="label">ATXN2</td> <td>Ataxin-2</td> </tr> <tr> <td class="label">Target</td> <td>Protein</td> </tr> <tr> <td class="label">NMDA receptor</td> <td>GRIN1/2</td> </tr> <tr> <td class="label">AMPA receptor</td> <td>GRIA1-4</td> </tr> <tr> <td class="label">Cytosolic [ROS](/entities/reactive-oxygen-species)</td> <td>SOD1</td> </tr> </table>
This page catalogs proteins that serve as direct or indirect targets for drug development in neurodegenerative diseases. Understanding drug target prioritization helps identify promising therapeutic approaches and track the drug development pipeline. [@alzheimers2024]
Drug targets in neurodegenerative diseases span multiple categories: proteins involved in disease pathogenesis, proteins regulating protein homeostasis, and proteins modulating cellular survival pathways. [@parkinsons2023]
--- [@als2023]
Alzheimer's Disease Drug Targets
Amyloid Pathway Targets
Tau Pathway Targets
Neurotransmission Targets
Neuroinflammation Targets
Parkinson's Disease Drug Targets
Alpha-Synuclein Targets
Dopamine Pathway Targets
LRRK2 Targets
ALS Drug Targets
Genetic Target Approaches
Neuroprotection Targets
Target Validation Considerations
Genetic Validation
GWAS hits provide human genetic validation
Mendelian mutations provide causal evidence
Polygenic scores can identify additive targets
Preclinical Validation
Knockout/knockin mouse models
In vitro assays using patient-derived cells
iPSC neuronal models
Clinical Validation
Biomarker engagement studies
Target occupancy measurements
Mechanistic biomarker readouts
Emerging Target Categories
Protein Homeostasis
[Autophagy](/entities/autophagy) enhancers
Proteasome modulators
Molecular chaperones
Cellular Rejuvenation
Senolytics
Cellular reprogramming factors
Youth factors (e.g., Klotho)
RNA Targets
RNA-binding proteins
Long non-coding RNAs
MicroRNAs
See Also
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Unknown, Alzheimer's Disease Drug Development Pipeline (2024) (2024)](https://doi.org/10.1002/alz.13847)
[Unknown, Parkinson's Disease Clinical Trials (2023) (2023)](https://doi.org/10.1016/j.tips.2023.01.005)
[Unknown, ALS Therapeutic Development (2023) (2023)](https://doi.org/10.1038/s41582-023-00798-0)
[Unknown, TREM2-Targeting Antibodies (2023) (2023)](https://doi.org/10.1038/s41591-023-02289-5)
Show full description